Modular Medical Secures Major Insurance Deals for Patch Pump

Modular Medical Secures Major Insurance Deals for Patch Pump

2026-11-19 companies

San Diego, Thursday, 19 November 2026.
Modular Medical secured coverage with the top three U.S. pharmacy benefit managers, opening access to over 182 million insured lives and roughly 80% of domestic prescription claims for its insulin pump.

Pivotal Coverage Gains Unlock Nationwide Access for Diabetics

Modular Medical, Inc. (NASDAQ: MODD) announced on November 18, 2026, that it has finalized reimbursement agreements with all three of the nation’s largest pharmacy benefit managers (PBMs) for its Pivot™ tubeless patch pump insulin delivery system [1][4]. These contracts, secured just days before a November 19 virtual fireside chat featuring CEO Jeb Besser, immediately grant access to over 182 million insured lives across commercial, Medicare, and Medicaid plans managed by the PBM networks [1][2][4]. The coverage encompasses roughly 80% of all domestic prescription claims, according to the Drug Channels Institute and MMIT Payor Report 2023 cited in Modular Medical’s announcement [1][GPT]. The timing of this development aligns with the company’s planned commercial rollout phase, which is currently underway in five U.S. regions and is expected to culminate in a full-scale launch in 2027 [2][4].

Commercialization Challenges and Financial Realities

Despite this operational milestone, Modular Medical faces significant financial headwinds as it transitions from development to commercialization. The company reported a net loss of $13.6 million for the six months ended September 30, 2026, with cash and cash equivalents totaling $5.1 million, down from $6.9 million at the beginning of the period [5]. Analysts caution that current cash levels may not sustain operations for a full 12 months without additional funding, particularly as initial shipments of the Pivot pump have generated no revenue to date [5]. The company’s financial statements for the quarter ended September 30, 2026, indicate a continued reliance on external capital, including $8.2 million in net proceeds from an at-the-market offering program between June and September 2026 [5]. The company’s independent auditor expressed substantial doubt about Modular Medical’s ability to continue as a going concern in its report on the consolidated financial statements for the year ended March 31, 2026 [5].

Technological Innovation and Market Positioning

The Pivot pump, cleared by the FDA in April 2026 and commercially available since June 2026, represents a next-generation alternative to traditional tubed insulin pumps and multiple daily injections [5]. Its tubeless, patch-based design is intended to simplify diabetes management and address barriers to broader adoption among patients who rely on injection therapy [5]. Modular Medical’s first-generation MODD1 pump received FDA 510(k) clearance in September 2024, and the company initiated human use trials for the Pivot system in August 2025 [5]. With the PBM coverage now secured, the company aims to transition patients from daily injections to advanced pump therapy through a phased commercial rollout, starting in select metropolitan markets and expanding nationwide over the next year [2][5].

Strategic Vision and Investor Implications

The securing of PBM coverage is widely viewed as a critical step toward achieving commercial viability for Modular Medical. CEO Jeb Besser emphasized in a November 19 fireside chat that these agreements establish a foundation for broader patient access through standard pharmacy benefits, reducing traditional reimbursement barriers [2][4]. Industry analysts note that the company’s ability to compete directly with established insulin pump incumbents will depend not only on reimbursement access but also on execution in manufacturing, distribution, and patient adoption [GPT]. While the company’s long-term financial performance remains uncertain, the PBM coverage significantly enhances its near-term prospects by unlocking access to a majority of U.S. insured lives [1][5]. Investors will be closely monitoring the company’s ability to scale production, drive adoption, and ultimately generate revenue from pump sales and related consumables in 2027 and beyond.

Sources


Medical devices Healthcare reimbursement